The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies.

By L. Adams, S. Sanderson, K. Lindor, P. Angulo. Journal of Hepatology, 2005

948 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/470b57f1eefc11814f5b8cc27654b8e6283c554c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. Z. Younossi
2. Megan H. Bair-Merritt
3. Q. Anstee
4. C. Day
5. A. Sanyal
6. S. Bellentani
7. G. Targher

In Epidemiology

1. Z. Younossi
2. Megan H. Bair-Merritt
3. A. Sanyal
4. Q. Anstee
5. C. Day
6. E. Brunt
7. S. Bellentani
8. L. Henry

In Hepatology

1. Z. Younossi
2. Megan H. Bair-Merritt
3. A. Sanyal
4. E. Brunt
5. C. Day
6. S. Bellentani
7. Q. Anstee
8. Z. Goodman

Citations in the corpus

• NONALCOHOLIC STEATOHEPATITIS IS ASSOCIATED WITH ALTERED HEPATIC MICRO RNA EXPRESSION (2008, methodology): “The distributions for multiplicity and cooperativity were based on (1) log2 rank of differentially expressed miRNAs versus number of gene targets (based on targets presented in Supporting Tables 1-6), and (2) log2 rank of gene targets versus number of miRNAs directed at them, respectively.”
• Increased Infiltration of Macrophages in Omental Adipose Tissue Is Associated With Marked Hepatic Lesions in Morbid Human Obesity (2006, background): “A recent longitudinal study in NAFLD patients, using sequential liver biopsy, showed that fibrosis progresses in 37% of patients, with a high variability in the rate of progression among subjects (34).”
• Association between Non-invasive Fibrosis Markers and Mortality among Adults with Non-alcoholic Fatty Liver Disease in the United States (2013, background): “Furthermore, characteristic features of NASH, such as steatosis, inflammation, and ballooning of hepatocytes, may diminish as fibrosis advances.(9,10) Although a consensus is lacking as to optimal surrogate indicators for NAFLD and NASH for large-scale, population-based, epidemiological studies, a n”
• Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. (2019, background): “BMI (when patients with cirrhosis were excluded), as well as T2DM were independent prognostic factors of the progression of fibrosis in another prospective study of NAFLD patients subjected to serial liver biopsies (range of follow up 1–21 years) [90].”
• Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver‐related mortality (2011, background): “In summary, our data confirm that patients with NASH are at high risk for LRM.(1-14,21-30) We have also shown that a certain degree of agreement exists between all four sets of pathologic criteria for NASH.”
• INCREASED HEPATIC SYNTHESIS AND DYSREGULATION OF CHOLESTEROL METABOLISM IS ASSOCIATED WITH THE SEVERITY OF NONALCOHOLIC FATTY LIVER DISEASE (2012, background): “NASH can progress to cirrhosis in up to 15% of affected subjects (Adams et al., 2005; Ekstedt et al., 2006).”
• A position statement on NAFLD/NASH based on the EASL 2009 special conference. (2010, methodology): “Pooled data [47–51] have shown that improvement occurs in only 21% of patients with progression in 38% (with some progressing by two stages or more or towards cirrhosis).”
• Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and Adolescents (2011, neutral): “Patients were assigned in a 1:1:1 ratio to 1 of 3 groups for 96 weeks of treatment, either (1) oral metformin (500 mg twice daily) and vitamin E placebo twice daily, (2) vitamin E (400 IU twice daily) and metformin placebo twice daily, or (3) vitamin E placebo and metformin placebo, each twice daily”